Security Alert

Beware of fraudulent messages impersonating amana.

We have been made aware of fraudulent emails, messages, and job offers circulating online from individuals falsely claiming to represent amana.

These scams may promise investment opportunities, employment, or financial rewards while requesting personal information, payments, or account details.

Please note that the only official amana website is
www.amana.app

Please also be aware of the following fraudulent domains impersonating amana:

amanacapital961
amana.live
getamana.com
client.amana-trade.com
amanatrade.net
amana-capital.net
amaanahcapitall.com

Deposit $200 to get a $100 trading bonus.

Use the promo code AMANAWEB.

Sign up now.*T&Cs Apply.

Terms & Conditions

  1. Offer valid for new users signing up on amana.
  2. How to Qualify for $100 Trading Bonus:
    • Sign up via the website.
    • Complete onboarding by providing the required details.
    • Enter promo code AMANAWEB at the final step.
    • Deposit $100 or more before your first trade.
    • Make your first trade.
  3. Once all steps are completed, you’ll receive a $100 non-withdrawable trading bonus.
  4. Bonuses are credited during the first week of every month.
  5. The bonus can only be used for trading and cannot be withdrawn.
  6. The campaign is exclusive to selected amana customers.
  7. amana reserves the right to cancel bonuses in cases of suspected fraud.
CYTK icon

CYTK

61.40 USD

-3.27%

Today

-2.21%

1D

Market is closed

Sun

Closed

Mon

4:30 PM ~ 10:59 PM

Tue

4:30 PM ~ 10:59 PM

Wed

4:30 PM ~ 10:59 PM

Thu

4:30 PM ~ 10:59 PM

Fri

4:30 PM ~ 10:59 PM

Sat

Closed

Loading chart...
1D
5D
1M
3M
1Y
MAX

Information

Name

Cytokinetics Inc

Currency

USD

Market Cap

8.66B

Avg Daily Volume

1.90M

52 Week High

88.31 USD

52 Week Low

58.05 USD

Trading Hours

See hours

Business Summary

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Top News

Cytokinetics

+1.69%

Cytokinetics to Participate in November Investor Conferences

tradingview.com

18h ago

No Image

Cytokinetics

+1.69%

Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026

tradingview.com

2d ago

No Image

Cytokinetics

+1.69%

Weekly Recap: MYQORZO Health Canada approval and Q3 2026 results date

tradingview.com

1w ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.


Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.


What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.


What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.